$ITOX
IIOT-OXYS, Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007976 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $16.38K $19.71K
YoY Change -66.84% -14.3%
Cost Of Revenue $46.32K $4.871K
YoY Change 855.05% -5.23%
Gross Profit -$29.94K $14.84K
YoY Change -167.21% -16.91%
Gross Profit Margin -182.78% 75.29%
Selling, General & Admin $308.2K $89.80K
YoY Change 119.95% -43.46%
% of Gross Profit 605.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $12.48K $17.02K
YoY Change 0.0% 36.49%
% of Gross Profit 114.67%
Operating Expenses $320.7K $102.3K
YoY Change 110.13% -40.29%
Operating Profit -$350.6K -$87.43K
YoY Change 224.48% -43.02%
Interest Expense -$243.2K $88.48K
YoY Change 40.94% 493.29%
% of Operating Profit
Other Income/Expense, Net $42.14K
YoY Change -62.08%
Pretax Income -$593.8K -$45.29K
YoY Change 111.61% 7.08%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$612.6K -$45.29K
YoY Change 103.06% 7.08%
Net Earnings / Revenue -3739.68% -229.74%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 406.8M shares 406.8M shares
Diluted Shares Outstanding 406.8M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $640.00 $17.79K
YoY Change -98.08% -48.1%
Cash & Equivalents $644.00 $17.79K
Short-Term Investments
Other Short-Term Assets $2.310K $17.80K
YoY Change -70.27% 129.09%
Inventory
Prepaid Expenses
Receivables $5.460K $10.92K
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.410K $46.51K
YoY Change -87.99% -20.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $199.1K $409.7K
YoY Change -55.15% -10.05%
TOTAL ASSETS
Total Short-Term Assets $8.410K $46.51K
Total Long-Term Assets $199.1K $409.7K
Total Assets $207.5K $456.2K
YoY Change -59.62% -11.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $219.6K $95.30K
YoY Change 64.57% -40.28%
Accrued Expenses $534.1K $513.9K
YoY Change 34.98% 56.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $435.0K $359.3K
YoY Change 19.78% -1.07%
Total Short-Term Liabilities $2.152M $2.005M
YoY Change 28.31% 30.82%
LONG-TERM LIABILITIES
Long-Term Debt $58.99K $75.00K
YoY Change -43.44% -28.09%
Other Long-Term Liabilities $1.000K $1.000K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $59.99K $76.00K
YoY Change -43.03% -27.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.152M $2.005M
Total Long-Term Liabilities $59.99K $76.00K
Total Liabilities $2.212M $2.081M
YoY Change 24.09% 27.05%
SHAREHOLDERS EQUITY
Retained Earnings -$10.44M -$9.831M
YoY Change 12.21% 9.17%
Common Stock $470.0K $406.8K
YoY Change 33.46% 31.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.623M -$2.244M
YoY Change
Total Liabilities & Shareholders Equity $207.5K $456.2K
YoY Change -59.62% -11.22%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$612.6K -$45.29K
YoY Change 103.06% 7.08%
Depreciation, Depletion And Amortization $12.48K $17.02K
YoY Change 0.0% 36.49%
Cash From Operating Activities -$17.14K -$49.42K
YoY Change -90.76% -60.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 63.87K
YoY Change -100.0% -25.32%
NET CHANGE
Cash From Operating Activities -17.14K -49.42K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 63.87K
Net Change In Cash -17.14K 14.45K
YoY Change 1704.21% -136.84%
FREE CASH FLOW
Cash From Operating Activities -$17.14K -$49.42K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001290658
CY2023Q3 ITOX Unearned Interest
UnearnedInterest
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50773
dei Entity Registrant Name
EntityRegistrantName
IIOT-OXYS, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2415252
dei Entity Address Address Line1
EntityAddressAddressLine1
705 Cambridge Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
307-3092
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
406815293 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17790 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33336 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10920 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28941 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17801 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7773 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
46511 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
70050 usd
CY2023Q3 ITOX Originall Issuance Discount On Note Receivable
OriginallIssuanceDiscountOnNoteReceivable
1911 usd
CY2022Q4 ITOX Originall Issuance Discount On Note Receivable
OriginallIssuanceDiscountOnNoteReceivable
4716 usd
CY2023Q3 ITOX Note Receivable Net
NoteReceivableNet
198089 usd
CY2022Q4 ITOX Note Receivable Net
NoteReceivableNet
195284 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
211562 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
248585 usd
CY2023Q3 us-gaap Assets
Assets
456162 usd
CY2022Q4 us-gaap Assets
Assets
513919 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
95300 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
133408 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
513889 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
395714 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31425 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31425 usd
CY2022Q4 ITOX Unearned Interest
UnearnedInterest
5151 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
359300 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
363167 usd
CY2023Q3 ITOX Shares Payable To Related Parties
SharesPayableToRelatedParties
18494 usd
CY2022Q4 ITOX Shares Payable To Related Parties
SharesPayableToRelatedParties
14624 usd
CY2023Q3 ITOX Salaries Payable To Related Parties
SalariesPayableToRelatedParties
420240 usd
CY2022Q4 ITOX Salaries Payable To Related Parties
SalariesPayableToRelatedParties
263516 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
566153 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
469873 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2004801 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1676878 usd
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
75000 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
104300 usd
CY2023Q3 ITOX Due To Stockholders
DueToStockholders
1000 usd
CY2022Q4 ITOX Due To Stockholders
DueToStockholders
1000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2080801 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1782178 usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
619200 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
544800 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
406815293 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
406815293 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
352174583 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
352174583 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
406816 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
352175 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7180357 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7141877 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9831038 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9307137 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2243839 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1813059 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456162 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
513919 usd
CY2023Q3 us-gaap Revenues
Revenues
19714 usd
CY2022Q3 us-gaap Revenues
Revenues
23003 usd
us-gaap Revenues
Revenues
98286 usd
us-gaap Revenues
Revenues
39503 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
4871 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
5140 usd
us-gaap Cost Of Revenue
CostOfRevenue
30330 usd
us-gaap Cost Of Revenue
CostOfRevenue
5650 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
14843 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
17863 usd
us-gaap Gross Profit
GrossProfit
67956 usd
us-gaap Gross Profit
GrossProfit
33853 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89795 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
158818 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
373734 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
543449 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12477 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12477 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
102272 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
171295 usd
us-gaap Operating Expenses
OperatingExpenses
410757 usd
us-gaap Operating Expenses
OperatingExpenses
580472 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
122089 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
125568 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-34600 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
277424 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
321 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-5504 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
321 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-207447 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
8205 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
5986 usd
us-gaap Interest Income Other
InterestIncomeOther
19983 usd
us-gaap Interest Income Other
InterestIncomeOther
11647 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
88477 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
14913 usd
us-gaap Interest Expense
InterestExpense
117001 usd
us-gaap Interest Expense
InterestExpense
278605 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42138 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
111137 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-131297 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-196981 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45291 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42295 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-474098 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-743600 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45291 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-42295 usd
us-gaap Net Income Loss
NetIncomeLoss
-474098 usd
us-gaap Net Income Loss
NetIncomeLoss
-743600 usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
17383 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6909 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
49803 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
31617 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62674 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49204 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-523901 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-775217 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
406815293 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
406815293 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
287269793 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
287269793 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
395579178 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
395579178 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256358480 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
256358480 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2179925 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2179925 usd
CY2023Q3 ITOX Sales Commissions Paid On Sale Of Series B Preferred Stock
SalesCommissionsPaidOnSaleOfSeriesBPreferredStock
-1240 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62674 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2243839 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2243839 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1813059 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1813059 usd
ITOX Common Stock Issued For Financing Commitment
CommonStockIssuedForFinancingCommitment
54195 usd
ITOX Sales Commissions Paid On Capital Raise
SalesCommissionsPaidOnCapitalRaise
-2324 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
825 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
40425 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-523901 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2243839 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2243839 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1571617 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1571617 usd
CY2022Q3 ITOX Common Stock Issued For Financing Commitment
CommonStockIssuedForFinancingCommitment
88292 usd
CY2022Q3 ITOX Sales Commissions Paid On Capital Raise
SalesCommissionsPaidOnCapitalRaise
-1766 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49204 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1534295 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1534295 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1264853 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1264853 usd
ITOX Common Stock Issued For Financing Commitment
CommonStockIssuedForFinancingCommitment
481657 usd
ITOX Sales Commissions Paid On Capital Raise
SalesCommissionsPaidOnCapitalRaise
-9633 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
900 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
90000 usd
ITOX Beneficial Conversion Feature Associated With Discounts
BeneficialConversionFeatureAssociatedWithDiscounts
-57149 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-775217 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1534295 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1534295 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-523901 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-775217 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
825 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
900 usd
ITOX Discount On Notes Receivable
DiscountOnNotesReceivable
-2805 usd
ITOX Discount On Notes Receivable
DiscountOnNotesReceivable
5661 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12400 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
37400 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18021 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5100 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10028 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-38108 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1588 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
125434 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
80398 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
96279 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
116023 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-5151 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
10192 usd
ITOX Increase Decrease In Shares Payable To Related Parties
IncreaseDecreaseInSharesPayableToRelatedParties
3870 usd
ITOX Increase Decrease In Shares Payable To Related Parties
IncreaseDecreaseInSharesPayableToRelatedParties
12221 usd
ITOX Increase Decrease In Salaries Payable To Related Parties
IncreaseDecreaseInSalariesPayableToRelatedParties
156724 usd
ITOX Increase Decrease In Salaries Payable To Related Parties
IncreaseDecreaseInSalariesPayableToRelatedParties
10526 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129417 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-471561 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
-0 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
200000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-200000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
54195 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
481657 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2324 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9633 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
62000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
187000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113871 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
659024 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15546 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12537 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33336 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46821 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17790 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34284 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
ITOX Conversion Of Convertible Notes Payable And Derivative Liabilities
ConversionOfConvertibleNotesPayableAndDerivativeLiabilities
40425 usd
ITOX Conversion Of Convertible Notes Payable And Derivative Liabilities
ConversionOfConvertibleNotesPayableAndDerivativeLiabilities
0 usd
ITOX Effect Of Adopting Asu202006
EffectOfAdoptingAsu202006
0 usd
ITOX Effect Of Adopting Asu202006
EffectOfAdoptingAsu202006
57149 usd
CY2023Q3 ITOX Working Capital
WorkingCapital
-1958290 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129417 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9831038 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zRo60CGDPJ62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_868_zbA0DV5Gtrc6">Use of Estimates</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related parties. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
49500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
49500 usd
CY2023Q3 ITOX Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
1085 usd
CY2023Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
211426 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
211562 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
248585 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
495000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
495000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
283438 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
246415 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
211562 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
248585 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12477 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12477 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37023 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
12341 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
49500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
49500 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
510000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
543167 usd
CY2023Q3 ITOX Deferred Financing Costs
DeferredFinancingCosts
-75700 usd
CY2022Q4 ITOX Deferred Financing Costs
DeferredFinancingCosts
-75700 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2023Q3 ITOX Convertible Notes Payable Net
ConvertibleNotesPayableNet
434300 usd
CY2022Q4 ITOX Convertible Notes Payable Net
ConvertibleNotesPayableNet
467467 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
359300 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
363167 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
75000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
104300 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62674 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49204 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-523901 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-775217 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
406815293 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
406815293 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
287269793 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
287269793 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
395579178 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
395579178 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256358480 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
256358480 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00084
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2868397 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
883747995 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
368836113 shares
CY2023Q3 ITOX Due To Stockholders
DueToStockholders
1000 usd
CY2022Q4 ITOX Due To Stockholders
DueToStockholders
1000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
406815293 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
352174583 shares
CY2023Q3 us-gaap Shares Issued
SharesIssued
4512329 shares
CY2022Q4 us-gaap Shares Issued
SharesIssued
2568493 shares
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
566153 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
469873 usd
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2868397 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.00084
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2868397 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00084
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2868397 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.00084
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y8M12D

Files In Submission

Name View Source Status
0001683168-23-007976-index-headers.html Edgar Link pending
0001683168-23-007976-index.html Edgar Link pending
0001683168-23-007976.txt Edgar Link pending
0001683168-23-007976-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
iiot_ex1001.htm Edgar Link pending
iiot_ex1002.htm Edgar Link pending
iiot_ex1003.htm Edgar Link pending
iiot_ex1004.htm Edgar Link pending
iiot_ex3101.htm Edgar Link pending
iiot_ex3102.htm Edgar Link pending
iiot_ex3201.htm Edgar Link pending
iiot_ex3202.htm Edgar Link pending
iiot_i10q-093023.htm Edgar Link pending
image_001.jpg Edgar Link pending
itox-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
itox-20230930_cal.xml Edgar Link unprocessable
itox-20230930_def.xml Edgar Link unprocessable
itox-20230930_lab.xml Edgar Link unprocessable
iiot_i10q-093023_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
itox-20230930_pre.xml Edgar Link unprocessable